Filing Analysis
Harvard Bioscience, Inc. filed a Current Report on Form 8-K to disclose an updated corporate slide presentation intended for use at upcoming industry and investor conferences in March 2026.
Key Facts
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The corporate slide presentation is dated March 2026 and is attached as Exhibit 99.1.
- The presentation provides updates and summaries of the company's business for the investment community.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Harvard Bioscience, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company hosted a conference call on March 12, 2026, to discuss the performance.
Key Facts
- Announced financial results for the three and twelve months ended December 31, 2025
- Scheduled a conference call for March 12, 2026, at 8:00 AM ET
- The filing includes Exhibit 99.1, the press release detailing the financial results
Harvard Bioscience (HBIO) has formalized employment agreements for its CEO and newly permanent CFO, while confirming a 1:10 reverse stock split effective March 13, 2026. The CEO's new contract includes a $100,000 bonus contingent on the successful refinancing of the company's credit facility, suggesting recent financial restructuring.
Red Flags
- 1:10 reverse stock split effective March 13, 2026, typically indicating delisting risk or price maintenance issues.
- CEO bonus specifically tied to 'successful refinancing' of debt, highlighting recent liquidity or credit pressure.
- Significant post-split equity grants (75k and 30k units) may be highly dilutive given the company's micro-cap status.
Key Facts
- CEO John Duke's base salary set at $515,000 with a $100,000 bonus for credit facility refinancing.
- Mark Frost appointed permanent CFO and Treasurer, effective March 6, 2026, with a $375,000 base salary.
- A 1:10 reverse stock split is confirmed for March 13, 2026.
- CEO and CFO target equity grants for 2026 are 75,000 and 30,000 RSUs respectively (post-split).
Harvard Bioscience stockholders approved a reverse stock split at a special meeting on March 6, 2026. The Board of Directors subsequently set a final ratio of 1-for-10, effective March 13, 2026, to reduce the outstanding share count.
Red Flags
- Reverse stock split (1-for-10 ratio) is a red flag escalator.
- Authorized shares remain at 80,000,000 despite the 90% reduction in outstanding shares, significantly increasing the potential for future dilution.
Key Facts
- Stockholders approved a reverse split ratio range of 1-for-5 to 1-for-15.
- The Board finalized the ratio at 1-for-10.
- The split is effective at 4:30 p.m. ET on March 13, 2026.
- Outstanding shares will be reduced from approximately 44,179,894 to approximately 4,471,989.
- Authorized shares will remain at 80,000,000.
- Split-adjusted trading begins on March 16, 2026, under the existing symbol HBIO with a new CUSIP.